Aristotle Capital Management
JAZZ icon

Aristotle Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Aristotle Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.9M Sell
111,697
-18,848
-14% -$4.13M 0.06% 122
2026
Q1 		$24.7M Sell
130,545
-28,292
-18% -$4.94M 0.05% 123
2025
Q4 		$27M Buy
158,837
+781
+0.5% +$120K 0.05% 123
2025
Q3 		$20.8M Sell
158,056
-7,514
-5% -$901K 0.04% 126
2025
Q2 		$17.6M Buy
165,570
+6,704
+4% +$728K 0.03% 125
2025
Q1 		$19.7M Sell
158,866
-37,072
-19% -$4.84M 0.04% 119
2024
Q4 		$24.1M Sell
195,938
-16,753
-8% -$1.97M 0.05% 123
2024
Q3 		$23.7M Buy
212,691
+15,455
+8% +$1.69M 0.04% 123
2024
Q2 		$21.1M Buy
197,236
+293
+0.1% +$32.2K 0.04% 123
2024
Q1 		$23.7M Sell
196,943
-261
-0.1% -$32K 0.04% 122
2023
Q4 		$24.3M Buy
197,204
+21,447
+12% +$2.68M 0.05% 118
2023
Q3 		$22.7M Buy
+175,757
New +$23.4M 0.05% 116

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Aristotle Capital Management's JAZZ Position: Q2 2026 in Review

Aristotle Capital Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 14% in Q2 2026, selling an estimated $4.13M and leaving 111,697 shares worth $26.9M. The position accounts for 0.06% of the portfolio, ranked #122.

Aristotle Capital Management first reported a position in JAZZ in Q3 2023 and has held it in 12 quarters since. The position peaked at $27M in Q4 2025. 643 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Aristotle Capital Management held 111,697 shares of Jazz Pharmaceuticals worth $26.9M as of Q2 2026.
  • Aristotle Capital Management sold 18,848 Jazz Pharmaceuticals shares in Q2 2026, an estimated $4.13M.
  • Jazz Pharmaceuticals made up 0.06% of Aristotle Capital Management's portfolio in Q2 2026, its #122 holding.
  • Aristotle Capital Management first reported a position in Jazz Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Aristotle Capital Management's Jazz Pharmaceuticals position peaked at $27M in Q4 2025.
  • 643 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Aristotle Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.